Galaxy Securities reported on October 24 that Zhejiang Jingxin Pharmaceutical (002020.SZ) released its third-quarter report. The company achieved revenue of 3.209 billion yuan in the first three quarters, a year-on-year increase of 9.68%; net income attributable to the shareholders of the listed company was 0.575 billion yuan, a year-on-year increase of 21.66%; net income after deducting non-recurring gains and losses was 0.494 billion yuan, a year-on-year increase of 13.16%; basic earnings per share was 0.67 yuan per share.
京新药业(002020.SZ):前三季度净利润5.75亿元,同比增长21.66%
Zhejiang Jingxin Pharmaceutical (002020.SZ): The net income for the first three quarters was 0.575 billion yuan, a year-on-year increase of 21.66%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.